Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand

Among brick-and-mortar businesses offering compounded glucagon-like peptide-1 receptor agonist (GLP-1 RA) products after semaglutide and tirzepatide shortages, what products are offered, what types of care and monitoring are provided for patients using them, and which compounding facilities supply them?In this cross-sectional study of 75 businesses in 2 US states, 7 reported offering oral formulations and 42 reported offering GLP-1 RAs combined with B vitamins. Twenty-three compounding suppliers were identified, of which 4 lacked sterile compounding licenses and 4 had been subject to disciplinary action.The compounded GLP-1 RA market remains robust, with diverse sourcing, posing complex clinical and regulatory challenges.

Corresponding Author: Michael J. DiStefano, PhD, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 E Montview Blvd, Aurora, CO 80045 (michael.j.distefano@cuanschutz.edu).

Link to the article in your story

We encourage you to link out to this article in your your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.